CAN 107
Alternative Names: CAN-107Latest Information Update: 28 Sep 2025
At a glance
- Originator WuXi Biologics
- Developer CANbridge Pharmaceuticals
- Class Antibodies
- Mechanism of Action Fibroblast growth factor 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported X-linked dominant hypophosphataemic rickets
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for preclinical development in X-linked dominant hypophosphataemic rickets in China
- 24 Aug 2021 Preclinical trials in X-linked dominant hypophosphataemic rickets in China (unspecified route), prior to August 2021 (CANbridge Pharmaceuticals pipeline, August 2021)
- 15 Jul 2021 CANbridge Pharmaceuticals and Privus Biologics entered into a collaboration agreement to develop biotherapeutics for Rare disease in China, prior to July 2021 (CANbridge Pharmaceuticals pipeline, August 2021)